JP2011524906A5 - - Google Patents

Download PDF

Info

Publication number
JP2011524906A5
JP2011524906A5 JP2011514619A JP2011514619A JP2011524906A5 JP 2011524906 A5 JP2011524906 A5 JP 2011524906A5 JP 2011514619 A JP2011514619 A JP 2011514619A JP 2011514619 A JP2011514619 A JP 2011514619A JP 2011524906 A5 JP2011524906 A5 JP 2011524906A5
Authority
JP
Japan
Prior art keywords
fluoro
phenyl
thiazolo
pyridin
phenylcyclopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011514619A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011524906A (ja
JP5571073B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/003666 external-priority patent/WO2009154775A1/en
Publication of JP2011524906A publication Critical patent/JP2011524906A/ja
Publication of JP2011524906A5 publication Critical patent/JP2011524906A5/ja
Application granted granted Critical
Publication of JP5571073B2 publication Critical patent/JP5571073B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011514619A 2008-06-20 2009-06-18 S1p1受容体作働薬およびその使用 Expired - Fee Related JP5571073B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7447608P 2008-06-20 2008-06-20
US61/074,476 2008-06-20
PCT/US2009/003666 WO2009154775A1 (en) 2008-06-20 2009-06-18 S1p1 receptor agonists and use thereof

Publications (3)

Publication Number Publication Date
JP2011524906A JP2011524906A (ja) 2011-09-08
JP2011524906A5 true JP2011524906A5 (enExample) 2012-08-02
JP5571073B2 JP5571073B2 (ja) 2014-08-13

Family

ID=41434357

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011514619A Expired - Fee Related JP5571073B2 (ja) 2008-06-20 2009-06-18 S1p1受容体作働薬およびその使用

Country Status (10)

Country Link
US (2) US7842685B2 (enExample)
EP (1) EP2306994B1 (enExample)
JP (1) JP5571073B2 (enExample)
AR (1) AR072185A1 (enExample)
AU (1) AU2009260726B2 (enExample)
CA (1) CA2728046A1 (enExample)
ES (1) ES2433579T3 (enExample)
MX (1) MX2010013555A (enExample)
TW (1) TW201000099A (enExample)
WO (2) WO2009154780A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR079980A1 (es) * 2010-01-13 2012-03-07 Sanofi Aventis Derivados de oxazolopirimidina sustituida en 2,5,7
TWI478929B (zh) 2010-01-13 2015-04-01 Sanofi Aventis 含2,5,7-經取代唑并嘧啶環之羧酸衍生物
AR079982A1 (es) * 2010-01-13 2012-03-07 Sanofi Aventis Derivados de acido carboxilico heterociclicos que comprenden un anillo de oxazolopirimidina 2,5,7- sustituido., composiciones farmaceuticas y procesos para prepararlos.
TWI482623B (zh) * 2010-01-14 2015-05-01 Sanofi Aventis 包含2,5-經取代的唑并嘧啶環之雜環性羧酸衍生物類
JP5841069B2 (ja) 2010-01-14 2016-01-06 サノフイ 2,5−置換されたオキサゾロピリミジン誘導体
NZ601113A (en) 2010-01-14 2013-07-26 Sanofi Sa Carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring
TW201206429A (en) * 2010-07-08 2012-02-16 Merck Serono Sa Substituted oxadiazole derivatives
JP5822934B2 (ja) 2010-09-15 2015-11-25 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft アザベンゾチアゾール化合物、組成物及び使用方法
US9206164B2 (en) * 2011-03-25 2015-12-08 Boehringer Ingelheim International Gmbh Pyrazole compounds as CRTH2 antagonists
US8580816B2 (en) * 2011-07-07 2013-11-12 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-b]pyridine ring
US8907093B2 (en) 2011-07-07 2014-12-09 Sanofi Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring
US8735402B2 (en) * 2011-07-07 2014-05-27 Sanofi Cycloalkyloxycarboxylic acid derivatives
US9321787B2 (en) 2011-07-07 2016-04-26 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-d]pyrimidine ring
WO2013158422A1 (en) 2012-04-17 2013-10-24 E. I. Du Pont De Nemours And Company Heterocyclic compounds for controlling invertebrate pests
CN104380596B (zh) * 2012-07-20 2018-01-02 三菱电机株式会社 保持框架和太阳能电池模块
HK1212699A1 (zh) 2013-02-20 2016-06-17 拜耳医药股份公司 作为mknk1抑制剂的取代的咪唑并[1,2-b]哒嗪类化合物
BR112016003348B1 (pt) 2013-08-21 2023-03-07 Alios Biopharma, Inc Compostos antivirais ou sais farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e seus usos
US10597401B2 (en) 2015-05-08 2020-03-24 Albany Molecular Research, Inc. Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof
IL252151A0 (en) 2017-05-07 2017-07-31 Fainzilber Michael Treatment of stress disorders
CN110831593A (zh) * 2017-06-14 2020-02-21 特维娜有限公司 用于调节s1p1活性的化合物及其使用方法
CN110256466A (zh) * 2019-07-31 2019-09-20 昆山迪安医学检验实验室有限公司 一种噻唑[5,4-b]-吡啶基生物活性化合物的制备方法及其抗肿瘤活性的检测
US11884655B2 (en) 2019-11-19 2024-01-30 Trevena, Inc. Compounds and methods of preparing compounds S1P1 modulators
CN115611793A (zh) * 2021-07-14 2023-01-17 山东新华制药股份有限公司 硫代酰胺类化合物的合成方法
CN116410213A (zh) * 2023-02-21 2023-07-11 武汉大学 一种合成3-碳基-1-硼基环类化合物的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000038350A (ja) 1998-05-18 2000-02-08 Yoshitomi Pharmaceut Ind Ltd 糖尿病治療薬
CA2424870A1 (en) 2000-10-05 2003-04-04 Takeda Chemical Industries, Ltd. Agents for promoting the proliferation or differentiation of stem cells or neural progenitor cells
US6951848B2 (en) 2001-03-12 2005-10-04 Millennium Pharmaceuticals, Inc., Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
US7622479B2 (en) 2001-11-26 2009-11-24 Takeda Pharmaceutical Company Limited Bicyclic derivative, its production and use
CA2472715A1 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Edg receptor agonists
ES2392167T3 (es) * 2003-04-30 2012-12-05 Novartis Ag Derivados aminopropanol como moduladores del receptor esfingosina-1-fosfato
EP1620413A2 (en) 2003-04-30 2006-02-01 Cytokinetics, Inc. Compounds, compositions, and methods
US7417065B2 (en) * 2003-05-19 2008-08-26 Irm Llc Immunosuppressant compounds and compositions
CA2583976A1 (en) 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Use of defined compounds for the manufacture of a medicament for preventing/treating diseases resulting from somatic mutations
US7919519B2 (en) * 2005-11-23 2011-04-05 Epix Pharmaceuticals Inc. S1P receptor modulating compounds and use thereof
US7855193B2 (en) * 2005-11-23 2010-12-21 Epix Pharmaceuticals, Inc. S1P receptor modulating compounds and use thereof
WO2007084857A2 (en) 2006-01-13 2007-07-26 President And Fellows Of Harvard College Methods and compositions for treating cell proliferative disorders
US8003662B2 (en) 2006-01-30 2011-08-23 Array Biopharma, Inc. Heterobicyclic thiophene compounds and methods of use
US8632937B2 (en) 2006-02-08 2014-01-21 Eastman Kodak Company UV-sensitive lithographic printing plate precursor with benzoxazole derivative and analogues thereof as sensitizer
EP2010524A2 (en) * 2006-03-21 2009-01-07 Epix Delaware, Inc. S1p receptor modulating compounds
US7989472B2 (en) * 2006-03-23 2011-08-02 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US20100055071A1 (en) 2006-11-21 2010-03-04 Martin Robert Leivers Anti-Viral Compounds
WO2008073865A2 (en) 2006-12-11 2008-06-19 Novartis Ag Method of preventing or treating myocardial ischemia
CA2679980A1 (en) * 2007-03-21 2007-09-27 Epix Pharmaceuticals, Inc. S1p receptor modulating compounds and use thereof
JP2008308448A (ja) 2007-06-15 2008-12-25 Sankyo Agro Kk (3−硫黄原子置換フェニル)へテロアリール誘導体
CA2699417A1 (en) * 2007-09-20 2009-03-26 Amgen Inc. S1p receptor modulating compounds and use thereof

Similar Documents

Publication Publication Date Title
JP2011524906A5 (enExample)
JP2013527202A5 (enExample)
JP2013512900A5 (enExample)
HRP20120144T1 (en) Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity
JP2013512899A5 (enExample)
JP2014502979A5 (enExample)
JP2020506171A5 (enExample)
RU2012127760A (ru) Bcl-2-селективные апоптоз-индуцирующие средства для лечения рака и иммунных заболеваний
JP2013531028A5 (enExample)
JP2017530983A5 (enExample)
JP2014526549A5 (enExample)
RU2012127790A (ru) Индуцирующие апоптоз агенты для лечения рака и иммунных и аутоиммунных заболеваний
JP2004525179A5 (enExample)
NZ597241A (en) Pharmaceutical dosage form for oral administration of a bcl-2 family inhibitor
JP2006504656A5 (enExample)
NZ626985A (en) Combination therapy (vemurafenib and a mdm2 inhibitor) for the treatment proliferative disorders
JP2017511794A5 (enExample)
JP2014062126A5 (enExample)
EA016687B8 (ru) Производные циклопропиламида
NZ598083A (en) New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
JP2009532438A5 (enExample)
JP2010533131A5 (enExample)
RU2009144846A (ru) Использование модулятора рецептора s1p
JP2022545698A (ja) アペリン受容体アゴニストのための方法および使用
JP2023062064A5 (enExample)